Antiretroviral therapy in developing countries: pharmacologic considerations

Simple item page
dc.creatorLamorde, Mohammed
dc.creatorByakika-Kibwika, Pauline
dc.creatorMerry, Concepta
dc.date2011-12-29T12:21:56Z
dc.date2011-12-29T12:21:56Z
dc.date2008
dc.date.accessioned2018-09-04T12:32:15Z
dc.date.available2018-09-04T12:32:15Z
dc.descriptionPurpose of review This article reviews recent studies in the field of clinical pharmacology of antiretroviral drugs and highlights the relevance of the findings to clinical practice in developing countries. Recent findings Differences in antiretroviral pharmacokinetics are associated with polymorphisms of genes encoding drug metabolizing enzymes. Inadequate concentrations of antiretrovirals in children are common. A study in African children found subtherapeutic concentrations in 40% of patients receiving efavirenz at recommended doses. Summary Recent findings on the pharmacokinetics of antiretroviral agents relevant to clinical practice in developing countries are reviewed. Widespread poverty impacts negatively on HIV/AIDS treatment and prevention efforts. Improved access to treatment, social and economic support and pharmacology research in target populations are needed.
dc.identifierLamorde M,Byakika-Kibwika P,Merry C. Antiretroviral therapy in developing countries: pharmacologic considerations Vol 3
dc.identifier1746-630X
dc.identifierhttp://hdl.handle.net/10570/273
dc.identifier.urihttp://hdl.handle.net/10570/273
dc.languageen
dc.publisherLippincott Williams & Wilkins
dc.subjectAnti-HIV agents
dc.subjectDeveloping countries
dc.subjectDrug interactions
dc.subjectPharmacokinetics
dc.subjectToxicity
dc.titleAntiretroviral therapy in developing countries: pharmacologic considerations
dc.typeJournal article, peer reviewed
Files
Collections
Dissertation and Thesis